[1]
Lundorff, MD, L., Sjøgren, DmSci, MD, P., Hansen, MD, O.B., Jonsson, MD, T., Nielsen, P.R. and Christrup, PhD, MSc(Pharm), L. 2013. Switching from high doses of pure µ-opioid agonists to transdermal buprenorphine in patients with cancer: A feasibility study. Journal of Opioid Management. 9, 4 (Jul. 2013), 255–262. DOI:https://doi.org/10.5055/jom.2013.0166.